SCHEMBL21402702

SCHEMBL21402702

CCOCCN1C(=O)CCC(N2C(=O)c3cccc([N+](=O)[O-])c3C2=O)C1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 3/20 0.53
CRBN Q96SW2 3/20 0.53
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
ACHE P22303 1/20 0.40
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA9 Q16790 2/20 0.37
CA4 P22748 1/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
APEX1 P27695 1/20 0.37
RECQL P46063 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4937839 0.90 DDB1 (0.55) DDB1CRBNKMT2AMEN1ACHE
SCHEMBL19359289 0.89 DDB1 (0.58) DDB1CRBNKMT2AMEN1ACHE
SCHEMBL19359396 0.87 DDB1 (0.60) DDB1CRBNKMT2AMEN1ACHE
SCHEMBL26996413 0.87 DDB1 (0.53) DDB1CRBNKMT2AMEN1ACHE
SCHEMBL4940007 0.85 DDB1 (0.49) DDB1CRBNKMT2AMEN1ATM
SCHEMBL4936560 0.85 DDB1 (0.58) DDB1CRBNKMT2AMEN1ACHE
SCHEMBL21402693 0.84 DDB1 (0.50) DDB1CRBNKMT2AMEN1
SCHEMBL4940448 0.83 DDB1 (0.49) DDB1CRBN
SCHEMBL19359463 0.83 DDB1 (0.58) DDB1CRBNKMT2AMEN1ACHE
SCHEMBL4929933 0.83 CRBN (0.42) DDB1CRBNKMT2AMEN1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12331030-B2 Piperidine-2,6-dione derivatives and ulcerative colitis treating TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD (CN) 2025-06-17 US disclosed
US-20240132466-A1 PIPERIDINE-2,6-DIONE DERIVATIVES AND ULCERATIVE COLITIS TREATING TIANJIN HEMAY PHARMACEUTICAL SCI TECH CO LTD (CN) 2024-04-25 US disclosed
US-11873287-B2 Piperidine-2,6-dione derivatives and ulcerative colitis treating TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD (CN) 2024-01-16 US disclosed
US-20220372013-A2 PIPERIDINE-2,6-DIONE DERIVATIVES AND CROHN'S DISEASE TREATING GANZHOU HEMAY PHARMACEUTICAL, CO., LTD (CN) 2022-11-24 US disclosed
US-11485724-B2 Piperidine-2,6-dione derivatives and ulcerative colitis treating TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD (CN) 2022-11-01 US disclosed
US-20220306600-A1 PIPERIDINE-2,6-DIONE DERIVATIVES AND ULCERATIVE COLITIS TREATING TIANJIN HEMAY PHARMACEUTICAL SCI TECH CO LTD (CN) 2022-09-29 US disclosed
US-20190352277-A1 PIPERIDINE-2,6-DIONE DERIVATIVES AND CROHN'S DISEASE TREATING TIANJIN HEMAY BIO TECH CO LTD (CN) 2019-11-21 US disclosed
EP-3546450-A1 PIPERIDINE-2,6-DIONE DERIVATIVE AND TREATMENT FOR ULCERATIVE COLITIS Tianjin Hemay Bio-Tech Co., Ltd (CN) 2019-10-02 EP disclosed
EP-3546449-A1 PIPERIDINE-2,6-DIKETONE DERIVATIVE AND TREATMENT FOR CROHN'S DISEASE Tianjin Hemay Bio-Tech Co., Ltd (CN) 2019-10-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132466-A1 PIPERIDINE-2,6-DIONE DERIVATIVES AND ULCERATIVE COLITIS TREATING DPYD, PTGDR2, UCK2 DDB1 3183/4885CRBN 3209/4885KMT2A 2058/4885
US-20190352277-A1 PIPERIDINE-2,6-DIONE DERIVATIVES AND CROHN'S DISEASE TREATING PTGDR2, PTGDR, TPMT DDB1 3702/4885CRBN 3060/4885KMT2A 1862/4885
US-12331030-B2 Piperidine-2,6-dione derivatives and ulcerative colitis treating DPYD, PTGDR2, UCK2 DDB1 3183/4885CRBN 3209/4885KMT2A 2058/4885
US-11485724-B2 Piperidine-2,6-dione derivatives and ulcerative colitis treating DPYD, PTGDR2, UCK2 DDB1 3183/4885CRBN 3209/4885KMT2A 2058/4885
US-11873287-B2 Piperidine-2,6-dione derivatives and ulcerative colitis treating DPYD, PTGDR2, UCK2 DDB1 3183/4885CRBN 3209/4885KMT2A 2058/4885
US-20220372013-A2 PIPERIDINE-2,6-DIONE DERIVATIVES AND CROHN'S DISEASE TREATING PTGDR2, PTGDR, TPMT DDB1 3702/4885CRBN 3060/4885KMT2A 1862/4885
US-20220306600-A1 PIPERIDINE-2,6-DIONE DERIVATIVES AND ULCERATIVE COLITIS TREATING DPYD, PTGDR2, UCK2 DDB1 3183/4885CRBN 3209/4885KMT2A 2058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.